For Patients with Multiple Myeloma, DTP3 May Be Effective
the Cancer Therapy Advisor take:
According to a study published in the journal Cancer Cell, researchers at Imperial College London in London, United Kingdom, have developed a novel cancer drug called DTP3 that has effectively killed myeloma cells in human cells and mice during laboratory tests. The drug did not cause any toxic adverse effects, a common problem with most other anticancer drugs. DTP3 works by inhibiting an important process involved with cancer cell proliferation.
By studying cancer cells from patients with multiple myeloma, the researchers identified GADD45β/MKK7, a protein complex that plays a key role in helping cancer cells to survive.
By targeting this protein complex with DTP3, the nuclear factor kappa B (NF-kB) signaling pathway, which is overactive in numerous types of cancer and responsible for preventing apoptosis, becomes interrupted, thereby leading to selective myeloma cell death. A key benefit of DTP3 is that it does not result in toxic side effects at the doses that have destroyed tumors in mice.
The researchers are optimistic that DTP3 could have therapeutic benefit for the treatment of patients with multiple myeloma and possibly other types of cancer. They hope to begin clinical trials next year.
A novel cancer drug called DTP3 has effectively killed myeloma cells in human cells.
Scientists at Imperial College London have developed a new cancer drug which they plan to trial in multiple myeloma patients by the end of next year. In a paper published today in the journal Cancer Cell, the researchers report how the drug, known as DTP3, kills myeloma cells in laboratory tests in human cells and mice, without causing any toxic side effects, which is the main problem with most other cancer drugs.
The new drug works by stopping a key process that allows cancer cells to multiply. The team have been awarded Biomedical Catalyst funding from the Medical Research Council (MRC) to take the drug into a clinical trial in multiple myeloma patients, scheduled to begin in late 2015. Multiple myeloma is an incurable cancer of the bone marrow, which accounts for nearly two per cent of all cancer deaths.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy